Astra Remains Strong In First Nine Months Of 96
In the first nine months of 1996 Swedish drug company Astra achieved sales of 28.1 billion Swedish kroner ($4.3 billion), an increase of 5%. The firm said that calculated at constant exchange rates, growth was 16%, which is the same as in the first half of the year. The firm said that price changes did not affect sales growth during the reporting period.
Pretax earnings were 9.8 billion kroner, up 8%, operating earnings advanced 8% to 9.1 billion kroner, and earnings per share were 11.40 kroner, up 6%.
Astra's turnover of its leading product, the antiulcerant Losec (omeprazole) totalled 12.7 billion kroner, up 12% (22% CER). Worldwide sales of the product were 17.8 billion kroner.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze